Jim Mazzo, the recently retired global president of Ophthalmic Devices for Carl Zeiss Meditec, and chairman of local medtech and technology accelerator Octane, has a new position.
He joined the board of Irvine-based implantable intraocular lens maker LensGen Inc.
“LensGen has a unique platform technology that I believe represents the future of cataract and lens replacement surgery,” Mazzo said in a statement.
LensGen also announced the initial closing of $10 million of a $20 million bridge financing, ahead of a large Series B round planned in early 2021 to fund the company’s pivotal clinical study.
The firm previously raised a $21 million Series A round in 2017. Both rounds of financing were led by Japan’s leading optical manufacturer, Hoya Group.
